BridgeMD
Tests treatment safety and results for Juvenile Psoriatic Arthritis
Official title A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
ClinicalTrials.gov ID: NCT06869551
What this study is testing
What is Deucravacitinib?
Deucravacitinib is an investigational medicine, being studied as a potential treatment for juvenile psoriatic arthritis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 5 to 17
You may be able to join if
- Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).
- Participants must have at least three joints that are affected by arthritis.
- Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.
You likely can't join if
- Participants must not have been diagnosed with JPsA before 5 years of age.
- Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,
- Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.
- Other protocol-defined Inclusion/Exclusion criteria apply.
The study team makes the final eligibility decision.
Where it's taking place
- Lancaster, California, United States
- Chicago, Illinois, United States
- Indianapolis, Indiana, United States
- North New Hyde Park, New York, United States
- Cincinnati, Ohio, United States
- Cleveland, Ohio, United States
- Austin, Texas, United States
- Fortaleza, Ceará, Brazil
- Cuiabá, Mato Grosso, Brazil
- Belo Horizonte, Minas Gerais, Brazil
- Curitiba, Paraná, Brazil
- Recife, Pernambuco, Brazil
- Porto Alegre, Rio Grande do Sul, Brazil
- Vila Clementino, São Paulo-SP, Brazil
- Rio de Janeiro, Brazil
- São Paulo, Brazil
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Beijing, Beijing Municipality, China
- Chongqing, Chongqing Municipality, China
+ 21 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 5 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lancaster, California, United States; Chicago, Illinois, United States; Indianapolis, Indiana, United States; North New Hyde Park, New York, United States; Cincinnati, Ohio, United States; Cleveland, Ohio, United States and 35 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.